On Friday, the U.S. Federal Food and Drug Administration (FDA) advisory board unanimously approved the use of Johnson & Johnson’s vaccine for revaccination against coronavirus.
The “booster dose” of the J&J vaccine is approved for Americans over the age of 18, provided that it is vaccinated no earlier than two months after the first dose of the vaccine.
During the hearing, the members of the FDA Advisory Board drew attention to the lower level of antibodies produced in J&J vaccinated compared to Pfizer and Moderna vaccines. In this regard, experts asked representatives of Johnson & Johnson if it was possible to make the vaccine two-dose. Recall that at the moment, one J&J vaccination is considered sufficient.
One of the vaccine developers, Dr. Dan Barouch, presented research data according to which the level of antibodies from the J&J vaccine was “significantly lower” than that of mRNA vaccines, but “the immune response remained stable.”
Dr. Eric Rubin, an infectious diseases expert representing the Faculty of Public Health at Harvard University, said that he expects that the second J&J vaccination will be safe for health and also pointed out the need for repeated doses due to the lower effectiveness first dose of the vaccine.
The FDA advisory board clarified that they would consider the proposal of a group of scientists to call the second J&J vaccination a “repeated-dose” and not a “revaccination.”
Recall that a “booster dose” of the Pfizer / BioNTech vaccine was officially approved last month in the United States. On October 14, the FDA Advisory board also unanimously supported revaccination with Moderna for Americans aged 65 and older and those who are at high risk due to possible complications from COVID-19 or are at risk of getting sick due to the peculiarities of their profession.